Protocol: Incidence rate, risk factors and patient reported outcome in patients with a dislocation following hip hemiarthroplasty after acute femoral neck fracture; a scoping review

Objective: The objective of this scoping review of the literature is to find the incidence rate and risk factors for dislocation of hip hemiarthroplasties (HAs) after acute femoral neck fractures (FNFs). Additionally we aim to determine the subjectively reported experience and/or Patient Reported Outcomes (PROs) minimum six months after a dislocation of a hip HA after acute FNF. Introduction: The existing literature suggests a dislocation rate of 1-12%(1-8), and we aim to evaluate the dislocation rates reported in the literature, and explain the differences in the reportings. Some of the suggested risk factors ranging from surgical approach(1, 5, 6), cognitive impairment(2, 5-8), prosthesis type(4) and uncemented vs cemented implant(3). There are no studies summarizing all risk factors for dislocating the hip HA. The patients subjective experience after dislocation of a hip HA after acute FNF is not well known. The literature lacks direct information of the patients subjective experience after dislocation of the hip HA after acute FNF. Inclusion criteria: Published articles on the incidence of patients with HA, who develop dislocation. Risk factors for dislocation and patient reported outcomes after reposition of dislocation. Register studies, clinical prospective studies and case-control studies will be included. The lower limit for inclusion of a risk factor will be minimum 5 studies that have minimum 10 patients with dislocation(s). Methods: This scoping review will be conducted in accordance with the JBI methodology for scoping reviews(9). We will develop a full search strategy for Embase, MEDLINE, PubMed and Cochrane Library. Studies published in English, Swedish, Danish and Norwegian will be included. Studies with other languages will be considered if an appropriate translator is available. The three research questions will be analyzed separately and reported narratively. Despite this being a scoping review, we shall include some risk of bias elements in the analysis. ### Competing Interest Statement Author Soren Overgaard has received personal payment for lecture/s from J & J and received payment to institution for lectures and course moderator from Heraeus. For all other authors there is no conflict of interest in this paper. ### Funding Statement This study did not recieve any funding, except for salary for phd-studies for the 1st author. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study will only use data that are openly avaliable to the public. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data is avaliable via PubMed, Embase, Medline and Cochrane Library.